



Individual Funding Request (IFR) Application Form

The clinical applicant (primary, secondary, tertiary or other) completing this form is responsible for collating all information and relevant evidence, which may involve working with other clinicians, outside of your organisation, involved in this patient's care. All forms must be typed, acronyms / abbreviations must be written out in full and all fields must be completed (or N/A stated where a field is not applicable). Incomplete mandatory fields and hand-written forms will result in the form being returned and may cause delays to consideration for funding. Please refer to your Clinical Commissioning Group's (CCGs) IFR policy or team (details at bottom form if any further support is required

Anonymity – please ensure that in order to protect patient identity, apart from section A, the patient is not referred to by name or initials within the application form.

Before completing this form, please answer the following questions	
Is this drug or non-drug request for a treatment currently commissioned by NHS	Yes 🗌 No 🗌
England? *	
If Yes , then STOP HERE and refer to NHS England.	
Drug requests	T
Is the requested intervention part of a clinical trial? **	Vec 🗆 Ne 🗆
If Yes, then STOP HERE. This funding route is not appropriate. Please speak to your trust	Yes ☐ No ☐
chief pharmacist regarding drug trials.	
Is the drug listed on the National Tariff excluded drug list and is for use in	Yes 🗌 No 🗌
accordance with a NICE Technology Appraisal Guidance / locally commissioned	
pathway? **	
If Yes, then STOP HERE. This funding route is not appropriate. Please redirect to the	
appropriate High Cost Drug (HCD) team.	Vaa 🗆 Na 🗆
Governance - Has the treatment been approved through the provider's clinical governance arrangements for the requested intervention for use? **	Yes ☐ No ☐
If No, then STOP HERE. The application requires trust governance approval. Evidence	
MUST be supplied e.g. drug and therapeutic committee (DTC) minutes, a letter from the DTC	
Chairman, if Chairman's action has been taken.	
Non drug requests	
Does the intervention requested fall under an existing policy (Treatment Access	
Policy (TAP), Effective Commissioning Initiative (ECI), Policy of Limited Clinical	
Value / Effectiveness (POLCV/E), prior approval)? ***	Yes ☐ No ☐
If Yes , and this application is being submitted by a GP, please check whether your CCG	
provides a referral management, clinical assessment or prior approval service.	
Has this request already been declined by a referral management/clinical	
assessment centre or Prior Approval Service? ***	Yes ☐ No ☐
If Yes , and the patient does not meet local policy criteria then your application needs to	
explicitly explain why your patient is clinically exceptional or rare in section G.	
Governance - Has the medical device/ intervention been approved in accordance	
with Provider's clinical governance arrangements ***	Yes ☐ No ☐
If No, then STOP HERE. The application requires approval. Evidence MUST be supplied e.g.	
minutes of the governance meeting where approval was given.	

Section A: Contact Informati	on *
1. Applicant details	Name *
The applicant should have clinical responsibility for this intervention for this patient for this specific clinical indication. Please ensure the declaration is	Designation/Job title *
	Telephone *
signed and dated (section I)	nhs.net address (no other emails accepted) *
2. Patient details	Initials *
	NHS number *
	Date of Birth (DoB) *
	Patient address *
	Registered consultant *
	Registered GP name *
	GP practice code *
	CCG *
	Date of referral *

Section B: Diagnosis *	
(Diagnosis refers to condition that the	e requested intervention will treat)
3. Patient diagnosis or	
condition (for which the	
intervention is requested) *	
4. Date of diagnosis and	
summary of any other relevant	
medical history *	
5. Does your patient have any	
other relevant diagnoses or co-	
morbidities? If yes, please list *	
6. What is the patient's current	
quality of life (QoL)? Please	
summarise the current status of	
the patient in terms of their QoL for	
example performing activities of	
daily living (please note the IFR	
panel cannot take social factors	
into consideration) *	
7. What is the severity of the	
current clinical condition, in	
relation to this diagnosis?	
Please use standard scoring	
systems e.g. World Health	
Organisation (WHO), Disease	
Activity Score (DAS28), cardiac	
index or those applicable to the	
patient's clinical diagnosis. Please	
include interpretation of the score	
where applicable *	

Section C: Interve		
	requested treatment, invest	gation, etc)
8. Details of	Name of intervention /f	
intervention (for	the intervention forms par	t
which funding is	of a drug regimen, please	
requested)	document the full regimen	
	(e.g. Drug X as part of	
	regimen Y (consisting of	
	drug V, drug W, drug X ar	nd
	drug Z) *	
	Type of Intervention *	Drug Procedure Device Other
	Planned duration	
	of intervention *	
	Dose and frequency	
	of drug **	
	Route of administration	
	of drug **	
9. Anticipated time	Your request will be acknown	owledged within 5 working days of receipt. A funding decision
frames		ocess up to 20 working days from the date of receipt of a full
		ed application with copies of supporting clinical papers and
	completion of section I.	
		than this? If the clinical decision needs to be made
		of clinical urgency, the trust should proceed at its own financial
		plication retrospectively. The decision to treat in the event of
		ing circumstances must be made in accordance with NHS
		governance mechanisms *
	approved provider (Trust)	governance mechanisms
	Yes 🗌 No 🗌	
	If 'Yes' please state why	this case is clinically urgent
10. Provider name*		Is this provider NHS commissioned? *
10.110Videi fidilie		Yes No
		If no, please explain why an NHS commissioned service is
		not appropriate
		not appropriate
11. Provider		
address *		
Section D: Compa	erison with Standard	Commissioned Intervention
•		Commissioned Intervention
12. What would be th	ne standard	Commissioned Intervention
12. What would be the intervention / manage	ne standard ement for	Commissioned Intervention
12. What would be the intervention / manage this patient at this sta	ne standard ement for age of their	Commissioned Intervention
12. What would be the intervention / manage	ne standard ement for age of their	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition?	ne standard ement for age of their	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the intervention of the intervention	ne standard ement for age of their *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the outcome from the standard in	ne standard ement for age of their *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the intervention of the intervention	ne standard ement for age of their *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the outcome from the standard in	ne standard ement for age of their *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the outcome from the standistance intervention for this part of the standistance in the s	ne standard ement for age of their * ne expected andard patient? *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the outcome from the standard in	ne standard ement for age of their the expected undard patient? *	Commissioned Intervention
12. What would be the intervention / manage this patient at this standisease / condition? 13. What would be the outcome from the standistervention for this patient. 14. What are the spe	ne standard ement for age of their ne expected indard patient? * cific e standard	Commissioned Intervention

^{*} Mandatory fields for all requests ** Mandatory fields for drug requests *** Mandatory fields for non-drug requests Page 3 of 8

Summary of all previous	Start	Stop	Name of		sponse
tervention(s) this patient has	date	date	Intervention		or stopping or
eceived for the condition *			for drugs include	indicate if	f still continuing
easons for stopping may include:			name, dose and		
Course completed			frequency of use		
No or poor response					
Disease progression Adverse effects/ poorly tolerated					
please detail nature of adverse					
ffect/intolerance)					
, , , , , , , , , , , , , , , , , , , ,					
lease add more lines if required					
-					
astion E. Evidonos for Effec	(:	of later.	antian Damasata d		
ection F: Evidence for Effect	liveness	of Interv	ention Requested		T
6. Is the requested intervention lic	ensed for	the reque	sted indication in the U	K? *	Yes ☐ No ☐
7. Evidence*					
is the applicant's responsibility to pro-	ovide robu	st relevant a	and valid evidence to su	pport the use	of the
tamanantian in this matiant					
tervention in this patient.					
·				,	
Il relevant evidence should be provid					
·	(NICE), So	cottish Medi	cines Consortium (SMC)), London (Ca	ancer) New

(a) What is the evidence that this intervention is likely to be effective

(b) Details of National, Regional or Local Guidelines/ Recommendations * (c) What are the anticipated benefits?*

(a) What would you consider to be a

(b) How and when will you monitor

(c) What is the minimum timeframe/
course of treatment at which a clinical

response can be assessed? *

(d) What criteria will be used to decide when the intervention is

Include details of the parameters

no longer effective? *

successful outcome for this intervention in this patient? *
Include details of the parameters you

in this type of patient? *

18. Outcomes *

intend to measure

this? *

Page 4 of 8

you intend to measure
 * Mandatory fields for all requests ** Mandatory fields for drug requests *** Mandatory fields for non-drug requests

19. What are most frequent anticipated adverse effects and what would their		
estimated frequency be? *		
20. Do the benefits outweigh the		
risks? If so in what way? * 21.What are the likely consequences		
for this patient if funding is not		
approved? *		
22. What are the other treatment		
options for this patient if funding is not approved? *		
not approved?		
Section C: Statement of Expensions	lity or Parity	
Section G: Statement of Exceptiona		
23. On which basis are you making this request? *	Exceptional clinical circums	stances (please continue to question 24)
•	•	ntation (please continue to question 25)
24. If exceptionality, please describe why this patient's clinical	(a) Please describe in detail how the clinical	
circumstances are exceptional *	presentation of this	
Give specific information in each section	patient differs from other	
opposite to indicate how this patient is	patients with this	
significantly different from the cohort of	condition	
other patients with the same clinical condition	(b) Please describe why	
ochamen.	and how this patient	
	might be expected to gain greater health	
	benefit from this	
	intervention compared	
	to other patients with	
	this condition	
25. If rarity, please describe why this	(a) Please state the UK	UK prevalence: Ref:
patient's condition or clinical presentation is so rare or unusual	prevalence and quote the source/reference	
that there is no relevant		
commissioning arrangement in	(b) Please describe how the clinical presentation of this	
place *	patient makes them rare *	
	(c) Please state, how many	
	patients with the same	
	condition or presentation as	
	this patient does your trust /	
	practice expect to see in the next 12 months? *	
	HEAL IZ HIUHUIS!	
Section H: Costs and Review for	Drug or Non Drug Interven	tions (to be completed by
approved NHS provider Chief Pharmacist	or Service Manager) *	tions (to be completed by
26. Total acquisition cost (inc VAT) for		
being applied for and associated costs s drug, phlebotomy, activity etc *	นษา สง สนาทิกเซเซากัน ส	
27. State the value of any offset costs *		
28. Please benchmark these costs agai contract prices *	nst London procurement	
29. Application reviewed by chief pharr nominated authorised deputy *	nacist / service manager or	Name:
nominated authorised deputy		Signature and email
		confirmation *:
		_1

SECTION I: APPLICANT'S DECLARATION *							
30. Declaration *	Yes No No						
I declare that this application is complete and ac							
necessary supporting information and evidence	has been provided on						
this form (and attachments)							
31. Patient consent *		Yes □ No □					
I confirm that the patient has given their explici	•						
identifiable data to be shared with the following							
facilitate their funding request; the patient's he		Oliviaal anniisanta nama and					
surgery and other clinicians and their organisa		Clinical applicants name and					
along with any sub-contractors (who are directly		job title:					
planning my care). The sharing of this informatic enable full consideration of this request. In							
vulnerable adult, I confirm I have complied with							
guidance and for people who are approving or							
consent has been lawfully obtained in accordance							
2004 and / or Mental Capacity Act 2005.							
• • •							
32. Correspondence and Contact *	Please copy the patient into						
The IFR team will copy the patient into correspor	correspondence. *						
progress and outcome of their application. If you	Yee O No O						
to be contacted or to receive correspondence ple	Yes No						
Responsible clinician name: *	Signature or email	Date: *					
Nesponsible chilician name.	Signature or email confirmation: *	DD/MM/YY					

Forward application to the IFR team (via Trust Service Agreements Department or equivalent, if applicable).

For SW London CCGs: Croydon, Kingston, Merton, Sutton, Richmond and Wandsworth Forms should be submitted to nelcsu.ifrswlondon@nhs.net Tel. enquiries: 020 3668 1222

For SE London CCGs: Lewisham, Bexley, Greenwich, Southwark and Lambeth Forms should be submitted to: nelcsu.selifr@nhs.net Tel. enquiries: 020 3049 4154

Patient Equality Monitoring Data *

NEL IFR wants to live up to the standards set out in its Equality and Diversity policy and to meet its legal obligations in respect of age, disability, gender, gender re-assignment, marriage/civil partnership, pregnancy and maternity, race or ethnic origin, religion or belief and sexual orientation.

We need your help and co-operation to enable us to do this. By providing this information you are helping us to ensure that our policies and practices do not discriminate. The information you provide will be treated in the strictest confidence, it will be separated from your application form prior to consideration by the IFR Panel.

		n unavailable to disclose									
	1	Ethnic Origin									
		White	British		Irish		Any other	er White b	ackground		
		Mixed	White a	and Black ean	White and African	Black	White a	nd Asian	Any other backgrou		
		Asian or Asian British	Indian 🗌		Pakistani	Pakistani		Bangladeshi		Any other Asian background	
		Black or Black British	Caribbo	ean 🗌	African		Any othe	er Black ba	ackground		
		Other Ethnic Groups	Chines	e 🗌	Any other 6	ethnic gro	up 🗌				
2 Sex											
		Male		Female		Transo	gender	1	Not disclosed	t 🗆	
	3	Sexuality	xuality					•			
	Heterosexual Bisexual				Gay		l	_esbian			
		Not disclosed									
	4	Age Group									
	16-25 🗌 26-35			36-45		4	16-55				
		56-65]	66+							
	5	Do you consid	er yours	self to have	e a disability?			1			
Registered disabled Unregister			Unregistered d	isabled		Not disal	bled				
		Nature of disal	oility								
		Hearing impairr	nent	Speech in	mpairment	Mobilit	y Impairm	ient /	Age related i	•	
		Viewel instruction		1	diaability	NA 4 -			Oth or	·	
		Visual impairme	ent 🗀	Learning	disability	ivienta	l health		Other		

6	Religion						
	No religion	Christian	Buddhist	Other			
	Hindu 🔲	Jewish	Muslim				
7	Gender Reassignment						
	Has patient Under gone gender reassignment?	Yes	No 🗆	Not disclosed			
8	Relationship Status						
	Married/Civil Partnership	Divorced	Single	Widowed			
	Not disclosed						
9	Pregnancy and materi	nity					
	Is the patient Pregnant or Breastfeeding?	Yes	No 🗆	Not disclosed			
10	Carers						
	Is the patient a Carer?	Yes	No 🗆	Not disclosed			